• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma - 28 Studies Found

Completed : Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
: Clear Cell Renal Cell Carcinoma
: 2015-10-06
: Drug: Nivolumab 3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to
Completed : Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
: Clear Cell Renal Cell Carcinoma
: 2015-11-16
: Drug: G-202 G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until dis
Completed : Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
: Metastatic Clear Cell Renal Cell Carcinoma
: 2016-05-19
:
  • Drug: Nivolumab Nivolumab IV,

Completed : Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
: Metastatic Clear Cell Renal Cell Carcinoma
: 2016-07-26
: Drug: Sunitinib
Active, not recruiting : Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
: 2012-08-16
:
  • Biological: Nivolumab Other Na

Completed : SLM + Axitinib for Clear Cell RCC
: Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
: 2015-08-17
:
  • Drug: Selenomethionine (SLM) S

Completed : Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma
: Clear Cell Renal Cell Carcinoma
: 2016-09-30
:
  • Drug: X4P-001 Continuous, oral

Not yet recruiting : Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
:
  • Clear Cell Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma
    : 2017-05-04
    :
    • Drug: Nivolumab Nivolumab will

Completed : Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
: Clear Cell Renal Cell Carcinoma
: 2008-01-03
:
  • Drug: Sorafenib Sorafenib 200

Completed : Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)
:
  • Clear Cell Renal Cell Carcinoma
  • Metastasis

: 2010-02-12
: Drug: Sunitinib 50mg daily(4 weeks on & 2 weeks off), 2 cycles, until progression or unacceptable to
Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.